What is one of the FDA label indications for metoprolol?

Metoprolol is a beta-blocker primarily used in the management of cardiovascular conditions. One of its key FDA-approved indications is for heart failure with reduced ejection fraction. In patients with this condition, metoprolol helps improve heart function, reduce the risk of hospitalization, and decrease mortality rates. It achieves these effects by lowering heart rate and decreasing myocardial oxygen demand, leading to an overall improvement in cardiac efficiency and health.

The other options, while related to various health conditions, do not pertain to the approved indications for metoprolol. Asthma and chronic obstructive pulmonary disease are conditions where beta-blockers are typically used with caution, as they can potentially exacerbate bronchospasm. Diabetes management is unrelated to the therapeutic applications of metoprolol. Thus, the focus on heart failure with reduced ejection fraction aligns with metoprolol's established role in cardiovascular therapy.